David R. Epstein Sells 370 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $53.31, for a total transaction of $19,724.70. Following the completion of the sale, the director now owns 27,524 shares in the company, valued at $1,467,304.44. This represents a 1.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tempus AI Trading Down 6.1 %

Shares of TEM opened at $64.99 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s fifty day simple moving average is $44.36 and its two-hundred day simple moving average is $48.84. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49.

Institutional Trading of Tempus AI

Several hedge funds have recently modified their holdings of TEM. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $67,000. IFP Advisors Inc bought a new position in Tempus AI in the fourth quarter worth approximately $76,000. US Bancorp DE acquired a new stake in Tempus AI in the fourth quarter valued at approximately $80,000. Finally, Vestor Capital LLC bought a new stake in shares of Tempus AI during the third quarter valued at approximately $153,000. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Wolfe Research started coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.